CN108452298A - A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells - Google Patents
A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells Download PDFInfo
- Publication number
- CN108452298A CN108452298A CN201710085260.7A CN201710085260A CN108452298A CN 108452298 A CN108452298 A CN 108452298A CN 201710085260 A CN201710085260 A CN 201710085260A CN 108452298 A CN108452298 A CN 108452298A
- Authority
- CN
- China
- Prior art keywords
- cell
- culture
- virus
- chick
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003837 chick embryo Anatomy 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 46
- 229960005486 vaccine Drugs 0.000 title claims abstract description 45
- 208000003152 Yellow Fever Diseases 0.000 title abstract description 15
- 230000002238 attenuated effect Effects 0.000 title abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 88
- 238000011218 seed culture Methods 0.000 claims abstract description 20
- 238000004108 freeze drying Methods 0.000 claims abstract description 16
- 230000006978 adaptation Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 229940031567 attenuated vaccine Drugs 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 97
- 238000011081 inoculation Methods 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 238000003306 harvesting Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000287828 Gallus gallus Species 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 210000002257 embryonic structure Anatomy 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000005723 virus inoculator Substances 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 239000012930 cell culture fluid Substances 0.000 claims description 5
- 239000006285 cell suspension Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000004448 titration Methods 0.000 claims description 4
- 239000002435 venom Substances 0.000 claims description 4
- 231100000611 venom Toxicity 0.000 claims description 4
- 210000001048 venom Anatomy 0.000 claims description 4
- 229960001515 yellow fever vaccine Drugs 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 239000012888 bovine serum Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 230000008520 organization Effects 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 210000001109 blastomere Anatomy 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 abstract description 5
- 239000003223 protective agent Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 9
- 239000012297 crystallization seed Substances 0.000 description 7
- 210000001161 mammalian embryo Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000287826 Gallus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to field of biological product, and in particular to a kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells.The present invention uses the 17D attenuated vaccine strains that WHO is provided, through seed culture of viruses, stroma cell of the chick-embryo cell that inoculating cell factory cultivates as Virus culture is made in chick-embryo cell adaptation of virus; virus liquid is collected after culture; using degerming, gelatin-free protective agent is added, then freeze-drying prepares finished product vaccine.Vaccine potency index accords with WHO regulations, and other quality control standards (QCS)s meet 2015 editions《Chinese Pharmacopoeia》Third portion requires.It is infected for preventing yellow fever.
Description
Technical field
The invention belongs to biotechnologies, and in particular to a kind of to produce yellow fever attenuated live vaccine with SPF chick-embryo cells
Technique.
Background technology：
Yellow fever is her mosquito-borne serious thermophilic visceral and Neural invasion viral infectious, and case fatality rate is very high, right and wrong
The public health problem that continent and many countries of South America pay special attention to.In Africa, 5.08 hundred million national population structures of the disease pair 33
At seriously threatening, African sub- the Sahara poverty-stricken area is mostly occurred in.It is at least reported every year with Endemic Areas such as Africa in South America
Case is more than 200,000, and death is more than 30,000.Though China is not at epidemic-stricken area, annual past as China's foreign economic opens
More and more, the biography of yellow fever come the personnel in Africa, South America torrid areas (labor service is outgoing, public affair accesses, tourism is on home leave)
It is very wide to broadcast medium-yellow-fever mosquito distribution, it is increasing to flavivirus potential hazard.Due to not treated targetedly to yellow fever
Measure, vaccine inoculation are the only effective prevention methods, thus to people going abroad's immunoprophylaxis prevention be it is extremely necessary, simultaneously
Also it to maintain vigilance to flavivirus bringing into through returned personnel, carry out the preparation of reply.
The current domestic production yellow fever vaccine in China.Annual about 300,000 person-portions are mainly used for people going abroad's inoculation.
These vaccines are inoculated with using SPF chick embryo yolk sacs, and chicken embryo tissue culture is ground to wait process that the crude vaccine of full embryo is made.By
More in impurity protein, there is insecurity, it is necessary to be improved.
For guarantor's vaccine safety, to vaccine, using production stroma cell, there are strict requirements for national Bureau of Drugs Supervision.Two
Times body cell is because coming from human normal tissue, by stringent calibrating, it was demonstrated that be a kind of safest cell, but because source has
Limit, cannot meet mass production needs.VERO cells come from
African green monkey kidney transformed cells have potential oncogenicity, although WHO is allowed for production of vaccine, have stringent
Generation limitation, country also formulated stringent residual DNA control standard.And general primary zooblast, there is external source because
Son pollution.For only SPF chick-embryo cells because material is easy to get, exogenous factor pollution is few to be classified as production of vaccine first choice by national Bureau of Drugs Supervision
Cell.
The present invention discloses a kind of safe yellow fever vaccine production technology, can equally reach existing chicken embryo production yellow fever and subtract
The vaccine potency and protecting effect that virus live vaccine WHO is required.This technique vaccine impurity is few, and side reaction is less than traditional processing technology system
The vaccine made, vaccine safety are more preferable.Production of vaccine efficiency can be greatly improved, reduce cost simultaneously.
Invention content
A kind of production technology with chick-embryo cell yellow fever attenuated live vaccine of the invention.Specially：It is trained using cell factory
Poultry blastocyte is Virus culture stroma cell, and inoculation passes through through the 17D attenuated vaccine strain seeds culture of viruses in chick-embryo cell adaptation of virus
Virus liquid is collected in culture, and finished product vaccine is prepared using freeze-drying after degerming, purifying, addition protective agent.
The present invention relates to a kind of Yellow Fever Vaccine,Live production technology is produced with chick-embryo cell culture 17D strains.Using thin
Chick-embryo cell is cultivated as Virus culture stroma cell by born of the same parents factory, is inoculated with the 17D attenuated vaccine strains through chick-embryo cell adaptation of virus
Seed culture of viruses collects virus liquid by culture, after filtering out bacterium, freeze drying protectant is added, freeze-drying prepares finished product vaccine.
In a preference, the 17D attenuated vaccine strain seeds culture of viruses used in the present invention are what the World Health Organization (WHO) provided
17D-204 strains (NIBS CODE 213-77).Chick-embryo cell is prepared with SPF chicken embryos.Chick-embryo cell seed culture of viruses used in the present invention
For seed culture of viruses of the inventor through chick-embryo cell adaptation of virus.Seed culture of viruses titre presses mouse LD50Method titre is not less than 5.60LD50；Plaque method
Titration is not less than 5.8LgPFU/mL.
In another preference, this vaccine bebcell cultural method is：
1) trypsin digestion and cells concentration 0.25%, pH are 7.4~7.6.
2) chick-embryo cells culture solution is containing 5% newborn bovine serum, 0.3% lactoalbumin hydrolysate, 1%NaHCO3, 2mM paddy ammonia
The MEM culture mediums of amide.
3) viruses culture solutions are the DMEM solution without cow's serum, and 2%~3%NaHCO is added3,
PH7.4~7.6, while adding 0.5% human albumin.
4) for the culture of chick-embryo cells using cell factory as culture carrier, cultivation temperature is 37 ± 0.1.
In another preference, vaccine preparation uses method：
1) viruses point kind method：Using cell factory culture chick-embryo cell.Chick-embryo cell presses 2~8 × 10 after digesting5/
cm2Cell number is inoculated into cell factory, cell culture fluid is added, 37 ± 0.1 DEG C of cultures, inoculated into chick embryo is thin after cell is at single layer
Born of the same parents' seed culture of viruses.
It is trained the cell of single layer, first the culture solution of falling virus removal, by 0.01~0.5 virus inoculations of MOI.After virus inoculation
Cell set 35 DEG C~37 DEG C 4~6 hours, make virus with cell come into full contact with absorption.Then prevent or cure a disease venom, it is slow with phosphate
Fliud flushing (PBS) is rinsed cell surface, is eventually adding the virus-culturing fluids of pH7.4~7.6, is sent into 35 DEG C~37 DEG C thermostatic chambers
It is cultivated.
2) viral miscegenation method is：After postdigestive cell suspension is sufficiently mixed by 0.001~0.1MOI virus inoculations, point
It is filled to cell factory, sets 35 DEG C~37 DEG C cultures.
The culture solution of falling virus removal after culture 48 hours, is rinsed cell surface with phosphate buffer (PBS), finally
Virus-culturing fluid is added, 35 DEG C~37 DEG C cultures are sent into pH7.4~7.6.
In another preference, the two methods virus harvest time be from be inoculated with after cultivate 72~96 hours after receive
Obtain virus.The virus liquid of harvest is again stoste, assay approval through 0.22 μm of aseptic filtration after 1 μm or 0.6 μm of filter membrane clarification
Addition freeze drying protectant carries out freeze-drying and vaccine is made afterwards.
In another preference, the ingredient that this patent vaccine protects freeze-drying shield agent solution is：PH7.4 without gelatin~
7.6DMEM polysaccharide solution.
Description of the drawings
Fig. 1 chick-embryo cell yellow fever attenuated live vaccine process flow charts (miscegenation).
Fig. 2 chick-embryo cell yellow fever attenuated live vaccines process flow chart (point kind).
The flow chart of the vaccine bebcell cultural method of Fig. 3 present invention.
Specific implementation mode
Below in conjunction with specific embodiment, the present invention will be further described.The present embodiment is only used for the description of the invention,
It is not construed as limiting the invention.
17D attenuated vaccine strain seeds culture of viruses used in the present invention are the 17D-204 strains that the World Health Organization (WHO) provides
(NIBS CODE 213-77) (Fig. 3).Chick-embryo cell is prepared with SPF chicken embryos.Chick-embryo cell seed culture of viruses used in the present invention is invention
Seed culture of viruses of the people through chick-embryo cell adaptation of virus.Seed culture of viruses titre presses mouse LD50Method titre is not less than 5.60LD50；Plaque method titrates not
Less than 5.8LgPFU/mL.
This vaccine bebcell cultural method is：
1) trypsin digestion and cells concentration 0.25%, pH are 7.4~7.6.
2) chick-embryo cells culture solution is containing 5% newborn bovine serum, 0.3% lactoalbumin hydrolysate, 1%NaHCO3, 2mM paddy ammonia
The MEM culture mediums of amide.
3) viruses culture solutions are the DMEM solution without cow's serum, and 2%~3%NaHCO is added3,
PH7.4~7.6, while adding 0.5% human albumin.
4) for the culture of chick-embryo cells using cell factory as culture carrier, cultivation temperature is 37 ± 0.1.
Vaccine preparation uses method：
1) viruses point kind method：
Using cell factory culture chick-embryo cell.Chick-embryo cell presses 2~8 × 10 after digesting5/cm2Cell number is inoculated into carefully
Born of the same parents factory, is added cell culture fluid, and 37 ± 0.1 DEG C of cultures wait for that cell is followed by kind of a chick-embryo cell seed culture of viruses at single layer.
It is trained the cell of single layer, first the culture solution of falling virus removal, by 0.01~0.5 virus inoculations of MOI.After virus inoculation
Cell set 35 DEG C~37 DEG C 4~6 hours, make virus with cell come into full contact with absorption.Then prevent or cure a disease venom, it is slow with phosphate
Fliud flushing (PBS) is rinsed cell surface, is eventually adding the virus-culturing fluids of pH7.4~7.6, is sent into 35 DEG C~37 DEG C thermostatic chambers
It is cultivated.
2) viral miscegenation method is：
After postdigestive cell suspension is sufficiently mixed by 0.001~0.1MOI virus inoculations, dispenses to cell factory, set 35
DEG C~37 DEG C of cultures.
The culture solution of falling virus removal after culture 48 hours, is rinsed cell surface with phosphate buffer (PBS), finally
Virus-culturing fluid is added, 35 DEG C~37 DEG C cultures are sent into pH7.4~7.6.
The two methods virus harvest time be after cultivate 72~96 hours from after being inoculated with harvest it is viral.The virus of harvest
Liquid through 0.22 μm of aseptic filtration is again stoste after 1 μm or the clarification of 0.6 μm of filter membrane, be added after assay approval freeze drying protectant into
Vaccine is made in row freeze-drying.
Embodiment 1, chick-embryo cell digestion
Chick-embryo cell comes from domestic SPF chicken embryos, takes the 9-10 day instar chicken embryos of normal development, and chicken is taken out in sterile working method
Embryo removes head and internal organ, is cleaned three times with PBS, is cut into 2-3mm tissue blocks with sterilizing medical operation, is added 0.25%
Trypsin solution digests 20 points of kinds, and centre gently shakes for 10 minutes makes trypsase be come into full contact with tissue block.
When digestion terminates, trypsin solution is removed.Then 4 are blown and beaten by 20,30,50,40 to tissue block with piping and druming suction pipe
Secondary, dynamics is by please be to gradual exacerbation.After having beaten every time, cell culture fluid, as cell suspension is added by per embryo 30ml.
Examples of implementation 2, chick-embryo cell are cultivated on cell factory and virus inoculation
1) virus point kind method is：
Using cell factory culture chick-embryo cell.Chick-embryo cell presses 2~4 × 10 after digesting5/cm2Cell number is inoculated into carefully
Born of the same parents factory, is added cell culture fluid, and 37 ± 0.1 DEG C of cultures wait for that cell is followed by kind of a chick-embryo cell seed culture of viruses at single layer.Specific method：
It is trained the cell of single layer, first the culture solution of falling virus removal, by 0.01~0.5 virus inoculations of MOI.After virus inoculation
Cell set 35 DEG C~37 DEG C 4~6 hours, make virus with cell come into full contact with absorption.Then prevent or cure a disease venom, it is slow with phosphate
Fliud flushing (PBS) is rinsed cell surface, is eventually adding the virus-culturing fluids of pH7.4~7.6, is sent into 35 DEG C~37 DEG C thermostatic chambers
It is cultivated.
Chick-embryo cell yellow fever attenuated live vaccine process flow chart (miscegenation) such as Fig. 1.
2) viral miscegenation method is：
After postdigestive cell suspension is sufficiently mixed by 0.001~0.1MOI and virus, by 3~5 × 105/cm2Packing is extremely
Cell factory sets 35 DEG C~37 DEG C cultures.
The culture solution of falling virus removal after culture 48 hours, is rinsed cell surface with phosphate buffer (PBS), finally
Virus-culturing fluid is added, 35 DEG C~37 DEG C cultures are sent into pH7.4~7.6.
In the above cell factory cell growth medium is added by every layer of 200ml.
Chick-embryo cell yellow fever attenuated live vaccine process flow chart (point kind) such as Fig. 2.
Embodiment 3, virus harvest
Virus inoculation 72 to 96 hours, when pathological development extremely +++~++++Virus can be harvested.
Examples of implementation 4：It is prepared by seed culture of viruses
Viral continuous passage is carried out with above method and prepares the yellow hot vaccine virus seeds of 17D, when titre reaches 5.6lgPFU/
Ml, which is believed that, obtains the 17D Strain that chick-embryo cell adapts to, and it is viral seed to carry out indices assay approval.
The calibrating of seed lot seed culture of viruses
Main seed lot should carry out following comprehensive calibrating：
1) discrimination test
Discrimination test is carried out using plaque method.By viral dilution to 50~100PFU/0.4ml, with yellow fever virus specificity
Immune serum and non-immune serum mixed in equal amounts in 37 ± 1 DEG C of water-baths and 60 minutes, are set 35 ± 1 DEG C and are cultivated 6 days, immune serum
The plaque number of group should be not less than 80% than the slip of non-immune serum group.Serum and cell controls should be set simultaneously, should be cloudy
Property；Virus control virus quantity should be 50~100PFU/0.4ml, should be positive.
2) virus titer
Plaque method can be used or mouse method carries out titration of virus.Main seed lot should use plaque method and mouse LD simultaneously50Method
Carry out titration of virus.
A. plaque method：
It takes seed culture of viruses to carry out 10 times of dilutions, then carries out 4 times and be serially diluted, take 3~4 acceptable diluent degree inoculation Vero cells,
It sets 35 ± 1 DEG C to cultivate 6 days, while setting cell controls, plaque number, virus titer are counted after Plaque Formation.It should be not less than
5.8LgPFU/ml。
B. mouse method：
It takes seed culture of viruses to carry out 10 times to be serially diluted, 10~12g of each dilution poison disease vaccination mouse 6, every intracerebral
0.03ml observes died in 21 days, 3 days and disregards, (animal dead quantity should must not exceed the 20% of experimental animal sum), meter
Calculate LD50.Virus titer should be not less than 5.50lgLD50/ml.
3) sterility test checks in accordance with the law, should meet 2015 editions《Chinese Pharmacopoeia》Regulation.
4) mycoplasma inspection checks in accordance with the law, should meet 2015 editions《Chinese Pharmacopoeia》Regulation.
5) viral exogenous factor inspection checks in accordance with the law, should meet 2015 editions《Chinese Pharmacopoeia》Regulation.
6) exogenous avian leukosis virus detection
Test sample is inoculated with SPF chicken embryos, culture is checked using enzyme-linked immunization after culture, as a result should be negative.
7) exogenous aviadenovirus detection
Test sample is inoculated with SPF Embryo liver cell cultures, detects training with suitable serological method respectively
As a result the I types and type III adenovirus for supporting object should be negative.
8) gene sequencing
Into the viral seed of cell continuous passage adaptation, its gene order is consistent with jungle fowl embryo culture virus seed.
9) monkey body test
Main seed lot carries out monkey body test.2015 editions should be met《Chinese Pharmacopoeia》Regulation.
1)~8 working seed lots should at least carry out) item assay approval.
First three batch vaccinogen liquid of the freshly prepd seed lot for when producing, continuously preparing should carry out viral key gene sequence
Row measure, and measurement result should be consistent with main seed lot.
10) virus seed conservation
Seed lot seed culture of viruses preserves after should being lyophilized in -60 DEG C or less.
Embodiment 5, virus harvest
Virus after harvest removes cell fragment host protein through 1 μm or 0.6 μm of membrane filtration with 0.2 μm of filter membrane degerming,
It is stoste that freeze drying protectant, which is added, and stoste should be placed in -20 DEG C of preservations.After and to freeze-drying sets 2 DEG C~8 DEG C in time after titre qualification
It preserves.
With preparation method of the present invention, vaccine primary quality measure is：
Malicious finished product titre is not less than 4.5IU/ml/ agent
Vaccine immunity dosage：0.5ml/ people
Egg white protein content：≤ 100ng/ agent
Antibiotic residual quantity：≤ 50ng/ agent
Cow's serum residual quantity：≤ 50ng/ agent
Pyrogen：≤ 5EU/ agent
Vaccine pH:7.2-8.0
Moisture is lyophilized：≤ 3%
Thermal stability:37 DEG C place 2 weeks after be not less than 4.5LgPFU/ml/ agent, 37 DEG C place 2 weeks after titre decline do not surpass
Cross 1.0LgPFU/ml.
Sterility test：Meet 2015《Chinese Pharmacopoeia》Third ministerial standard is qualified.
Mycoplasma inspection：Meet 2015《Chinese Pharmacopoeia》Third ministerial standard is qualified.
Abnormal toxicity test：Meet 2015《Chinese Pharmacopoeia》Third ministerial standard is qualified.
Discrimination test：It is qualified.
It should be understood that after reading the above teachings of the present invention, those skilled in the art can make the present invention
Various changes or modification, these equivalent forms also fall within the scope of the appended claims of the present application.
Claims (6)
1. producing Yellow Fever Vaccine,Live production technology with chick-embryo cell culture 17D strains the present invention relates to a kind of.Its feature exists
In：Using cell factory culture chick-embryo cell as Virus culture stroma cell, 17D of the inoculation through chick-embryo cell adaptation of virus subtracts
Toxic vaccine strain seed culture of viruses collects virus liquid by culture, after filtering out bacterium, freeze drying protectant is added, freeze-drying prepares finished product epidemic disease
Seedling.
2. preparation method according to claim 1, the 17D attenuated vaccine strain seeds culture of viruses used in the present invention are the World Health Organization
(WHO) the 17D-204 strains (NIBS CODE213-77) provided.Chick-embryo cell is prepared with SPF chicken embryos.Chicken used in the present invention
Blastocyte seed culture of viruses is seed culture of viruses of the inventor through chick-embryo cell adaptation of virus.Seed culture of viruses titre presses mouse LD50Method titre is not less than
5.60LD50；The titration of plaque method is not less than 5.8LgPFU/mL.
3. preparation method according to claim 1, this vaccine bebcell cultural method are：
1) trypsin digestion and cells concentration 0.25%, pH are 7.4~7.6.
2) chick-embryo cells culture solution is containing 5% newborn bovine serum, 0.3% lactoalbumin hydrolysate, 1%NaHCO3, 2mM glutamine
MEM culture mediums.
3) viruses culture solutions are the DMEM solution without cow's serum, and 2%~3%NaHCO is added3, pH7.4~7.6 are mended simultaneously
Add 0.5% human albumin.
4) for the culture of chick-embryo cells using cell factory as culture carrier, cultivation temperature is 37 ± 0.1.
4. vaccine preparation method according to claim 1, vaccine preparation uses method：
1) viruses point kind method：Using cell factory culture chick-embryo cell.Chick-embryo cell presses 2~8 × 10 after digesting5/cm2Carefully
Born of the same parents' number is inoculated into cell factory, and cell culture fluid is added, and 37 ± 0.1 DEG C of cultures wait for that cell is followed by kind of a chick-embryo cell poison at single layer
Kind.
It is trained the cell of single layer, first the culture solution of falling virus removal, by 0.01~0.5 virus inoculations of MOI.It is thin after virus inoculation
Born of the same parents set 35 DEG C~37 DEG C 4~6 hours, and virus is made to come into full contact with absorption with cell.Then prevent or cure a disease venom, use phosphate buffer
(PBS) cell surface is rinsed, is eventually adding the virus-culturing fluids of pH7.4~7.6, be sent into 35 DEG C~37 DEG C thermostatic chambers and carry out
Culture.
2) viral miscegenation method is：After postdigestive cell suspension is sufficiently mixed by 0.001~0.1MOI virus inoculations, packing is extremely
Cell factory sets 35 DEG C~37 DEG C cultures.
The culture solution of falling virus removal after culture 48 hours, is rinsed cell surface with phosphate buffer (PBS), is eventually adding
35 DEG C~37 DEG C cultures are sent into virus-culturing fluid, pH7.4~7.6.
5. vaccine preparation method according to claim 1, the two methods virus harvest time be from after being inoculated with culture 72~
Start harvest virus after 96 hours.The virus liquid of harvest is again through 0.22 μm of aseptic filtration after 1 μm or the clarification of 0.6 μm of filter membrane
Stoste, freeze drying protectant is added after assay approval carries out freeze-drying vaccine is made.
6. preparation method according to claim 1, the ingredient that the vaccine protects freeze-drying shield agent solution are：Without gelatin
PH7.4~7.6DMEM polysaccharide solutions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710085260.7A CN108452298A (en) | 2017-02-17 | 2017-02-17 | A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710085260.7A CN108452298A (en) | 2017-02-17 | 2017-02-17 | A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108452298A true CN108452298A (en) | 2018-08-28 |
Family
ID=63228992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710085260.7A Withdrawn CN108452298A (en) | 2017-02-17 | 2017-02-17 | A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108452298A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909905A (en) * | 2020-09-14 | 2020-11-10 | 天津中逸安健生物科技有限公司 | Concentration and preservation method of mumps attenuated live vaccine virus |
| CN112342185A (en) * | 2020-11-11 | 2021-02-09 | 深圳市卫光生物制品股份有限公司 | Bioreactor process for chick embryo cell rabies virus |
| CN113373107A (en) * | 2021-01-29 | 2021-09-10 | 上海生物制品研究所有限责任公司 | Method for producing virus by preparing passage chick embryo cells in large scale |
| CN115627259A (en) * | 2022-11-30 | 2023-01-20 | 北京赛尔富森生物科技有限公司 | Adaptation method of virus in chick embryo fibroblast |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103100083A (en) * | 2011-11-10 | 2013-05-15 | 北京佰康安生物科技有限公司 | Vaccine and preparation method thereof |
| CN103127496A (en) * | 2011-11-30 | 2013-06-05 | 普莱柯生物工程股份有限公司 | III type turkey herpes virus freeze-drying vaccine |
-
2017
- 2017-02-17 CN CN201710085260.7A patent/CN108452298A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103100083A (en) * | 2011-11-10 | 2013-05-15 | 北京佰康安生物科技有限公司 | Vaccine and preparation method thereof |
| CN103127496A (en) * | 2011-11-30 | 2013-06-05 | 普莱柯生物工程股份有限公司 | III type turkey herpes virus freeze-drying vaccine |
Non-Patent Citations (3)
| Title |
|---|
| 刘尧倩: "WHO关于黄热病疫苗的意见书", 《国际生物制品学杂志》 * |
| 李淑云 等: "鸡胚细胞制备17D黄热疫苗", 《中国生物制品学杂志》 * |
| 王锡岩: "17D黄热病病毒在鸡胚细胞上的适应性传代及其相关特性的研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909905A (en) * | 2020-09-14 | 2020-11-10 | 天津中逸安健生物科技有限公司 | Concentration and preservation method of mumps attenuated live vaccine virus |
| CN111909905B (en) * | 2020-09-14 | 2022-04-12 | 天津中逸安健生物科技有限公司 | Concentration and preservation method of mumps attenuated live vaccine virus |
| CN112342185A (en) * | 2020-11-11 | 2021-02-09 | 深圳市卫光生物制品股份有限公司 | Bioreactor process for chick embryo cell rabies virus |
| CN112342185B (en) * | 2020-11-11 | 2022-12-02 | 深圳市卫光生物制品股份有限公司 | Bioreactor process for chick embryo cell rabies virus |
| CN113373107A (en) * | 2021-01-29 | 2021-09-10 | 上海生物制品研究所有限责任公司 | Method for producing virus by preparing passage chick embryo cells in large scale |
| CN113373107B (en) * | 2021-01-29 | 2022-12-30 | 上海生物制品研究所有限责任公司 | Method for producing virus by preparing passage chick embryo cells in large scale |
| CN115627259A (en) * | 2022-11-30 | 2023-01-20 | 北京赛尔富森生物科技有限公司 | Adaptation method of virus in chick embryo fibroblast |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2172543B1 (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| US6656720B2 (en) | Animal cells and processes for the replication of influenza viruses | |
| CN110093307A (en) | The method for adapting to the BHK-21-SC cell strain of serum free suspension culture and preparing vaccine antigen with the cell strain | |
| CN108452298A (en) | A kind of technique producing yellow fever attenuated live vaccine with SPF chick-embryo cells | |
| CN106390112A (en) | Preparation method for triple inactivated vaccine of recombinant Newcastle disease, bird flu and infectious bronchitis | |
| CN102258777A (en) | Method for preparing inactivated vaccine and combined vaccine by breeding infectious bursal disease virus (IBDV) by chicken embryo source cell line | |
| CN104922665A (en) | Triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza | |
| CN101690808A (en) | Method for preparing swine fever-pseudorabies bigeminal live vaccine and product thereof | |
| CN108992674A (en) | A kind of heat resisting protective and its application | |
| CN104338127A (en) | Method for producing inactivated vaccine of H9N2 subtype of avian influenza virus and product of inactivated vaccine | |
| CN102727883B (en) | Combined live vaccine against porcine reproductive and respiratory syndrome and swine fever, and application thereof | |
| CN104774811A (en) | Swine pseudorabies virus PRV-YF strain and application thereof | |
| Duchene et al. | Production of poliovirus vaccines: past, present, and future | |
| CN105886477A (en) | Virus strain capable of being used for preparing VII-type Newcastle disease vaccine and coding gene thereof | |
| CN102965344B (en) | Production of infectious bronchitis virus and vaccine from cell line | |
| CN106563125B (en) | Duck hepatitis A virus III type compound live vaccine and preparation method thereof | |
| CN103937753A (en) | H9N2 subtype avian influenza virus strain as well as inactivated vaccine and application thereof | |
| CN107320721B (en) | Vaccine composition and preparation method thereof | |
| Abisheva et al. | AK‐2011 strain for the development of a vaccine against equine rhinopneumonitis | |
| CN114015658B (en) | Bivalent inactivated vaccine for H9N2 subtype avian influenza and chicken bursa mycoplasma | |
| CN102805863B (en) | Preparation method of novel bunyavirus purification inactivated vaccine by culturing human diploid cell | |
| CN105582535A (en) | Preparation method of CSF (Classical Swine Fever) and PR (Pseudorabies) bivalent live vaccine and product of CSF and PR bivalent live vaccine | |
| CN104357406A (en) | Rabies virus SNK-CTN strain and application thereof | |
| CN112080478B (en) | Efficient propagation method and application of H5 subtype avian influenza virus | |
| CN104328090B (en) | A kind of porcine pseudorabies virus strain, vaccine composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180828 |